Xing-yu Cao
Si Pu Lan Road
Langfang, China
Langfang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Gemtuzumab Ozogamicin-Containing Salvage Strategies as a Bridge to Second Allogeneic Hematopoietic Stem Cell Transplantation in Post-transplant Relapsed AML.
Journal: Transplantation and cellular therapy
Published: June 09, 2026
Peritransplant KMT2A-r Molecular MRD Dynamics and Relapse Timing Stratify Outcomes After Allo-HSCT in CR1 Acute Leukemia.
Journal: Transplantation and cellular therapy
Published: May 26, 2026
Long-Term Outcomes of Second Allogeneic Transplantation Following CD7 CAR-T in Remission for T-Cell Acute Lymphoblastic Leukemia or Lymphoma.
Journal: Transplantation and cellular therapy
Published: March 16, 2026
Low SOS/VOD Risk with Inotuzumab Ozogamicin as a Bridging Strategy to Second Allogeneic HSCT: A Real-World Study in Post-Transplant Relapsed B-ALL.
Journal: Transplantation and cellular therapy
Published: March 16, 2026
Superior long-term survival with acceptable safety of ATG/G-CSF-based haplo-HSCT with intensified BU+MEL/TT conditioning in CR Pediatric Non-DS-AMKL.
Journal: Frontiers in oncology
Published: November 07, 2025
Case Report: Targeting the Achilles' heel of monomorphic epitheliotropic intestinal T-cell lymphoma.
Case Report: Targeting the Achilles' heel of monomorphic epitheliotropic intestinal T-cell lymphoma.
Journal: Frontiers in oncology
Published: September 22, 2025
Case Report: Refractory systemic nmastocytosis with AML1::ETO+ acute myeloid leukemia driven by rare KIT mutation: remarkable therapeutic efficacy of avapritinib.
Journal: Frontiers in pediatrics
Published: June 12, 2025
Augmented myeloablative conditioning with olaparib in allogeneic hematopoietic stem cell transplantation for relapsed/refractory RUNX1::RUNX1T1-positive acute myeloid leukemia.
Journal: Frontiers in oncology
Published: April 09, 2025
Case Report: Rapid response to gemtuzumab-ozogamicin in a pediatric patient with refractory systemic mastocytosis with AML1::ETO+ acute myeloid leukemia.
Journal: Frontiers in immunology
Published: January 25, 2025
Human leukocyte antigen evolutionary divergence as a novel risk factor for donor selection in acute lymphoblastic leukemia patients undergoing haploidentical hematopoietic stem cell transplantation.
Journal: Frontiers in immunology
Published: May 30, 2024
Case report: NUP98::LEDGF fusion gene drives malignant hematological tumor with mixed immunological phenotype.
Journal: Frontiers in oncology
Published: March 16, 2024
A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T-cell therapy.
Journal: British journal of haematology
Published: January 25, 2024
Last Updated: 09/26/2026